Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Max Eldridge

Max has more than ten years in Life Sciences recruitment, He collaborates with executives to foster growth in Pharma, Biotech, CRO, TechBio, and Medical Device sectors​

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2025 | Hlx Life Sciences

Site by theLEAP

Go to Top